home / lobbying / lobbying_activities

lobbying_activities: 3426559

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3426559 45c05a6e-7208-4c7b-a782-fffca1372f72 Q3 LABORATORY CORPORATION OF AMERICA HOLDINGS 401104793 LABORATORY CORPORATION OF AMERICA HOLDINGS 2025 third_quarter HCR Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development. HOUSE OF REPRESENTATIVES,SENATE   270000 0 0 2025-10-01T11:42:08-04:00
Powered by Datasette · Queries took 26.63ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API